Recombinant Antibodies: Covagen AG presents the Fynomer technology

Tid 14 Juni 2010 – 18 Juni 2010

Plats The Crowne Plaza Berlin City Centre, Germany

Speaker: Dr. Simon Brack, Head of Lead Discovery, Covagen AG, Zürich, Switzerland Topic: Fynomers Neutralizing IL-17A: Making Use of Fc fusion protein We will present the versatility and broad applicability of the Fynomer technology. As an example, the isolation and characterization of high-affinity Fynomers capable of neutralizing IL-17 will be shown. Furthermore, engineered Fynomer-Fc fusion proteins having appropriate physico-chemical and in vivo half-life properties are attractive drug candidates for pre-clinical and clinical development. For more info about the event please visit www.informaglobalevents.com/event/antibodies

Kategorier

  • biosensor
  • attana
  • attana a200
  • fynomer
  • drug candidate

Relaterad media

Relaterat innehåll

  • Characterisation of complex lectin-cell kinetics (Attana Application Example)

    Attana Cell 200 - Label free, real time kinetics on cells, exploring biology on a new level!
     
    In the development process of new pharmaceutical compounds, kinetic experiments provide insights
    into potential drug candidates while also defining lead targets. In this application example we demonstrate the ability of the Attana Cell™ 200 to provide a complete and highly relevant analysis of a

  • PEGS 2010 with Attana!

    We are happy to have met so many industry people during the Protein Engineering Summit 2010 in Boston last week, and if you were there but didn't get the chance to taste our exquisite espresso you are welcome to stop by our booth during our upcoming events!

  • Biotech companies - Ways to work more efficiently

    Ernst & Young recently released their 24th annual report Beyond borders: global biotechnology report 2010, presenting, among other things, five guiding principles for biotech companies working in the new economy where funding is scarce and customers careful:
    Seizing funding opportunities. Companies need to broaden the search for capital to include nontraditional (and non-dilutive) sourc

Relaterade event

Fyll i din epostadress för att följa Attana AB

När du väljer att skapa ett konto och följa ett nyhetsrum kommer dina personuppgifter behandlas av oss och av ägaren av nyhetsrummet för att du ska kunna motta nyheter och uppdateringar enligt dina bevakningsinställningar.

För att läsa mer om detta, var vänlig läs vår Integritetspolicy som berör vår behandling av dina personuppgifter, och Integritetspolicy för Contacts som berör behandlingen av dina personuppgifter från ägaren av nyhetsrummet du följer.

Vänligen notera att våra Användarvillkor gäller alla våra tjänster.

Du kan dra tillbaka ditt samtycke när som helst genom att avregistrera dig eller genom att ta bort ditt konto.
Kolla din inkorg

Mejl skickat till __email__. Klicka på länken i mejlet för att följa Attana AB.

Okej